ANI Pharma (ANIP) Tops Q4 EPS by 8c, Revenues Beat; Offers FY19 EPS/Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
ANI Pharmaceuticals (ANIP) PT Raised to $73 at Raymond James
February 28, 2019 7:42 AM ESTRaymond James analyst Elliot Wilbur raised the price target on ANI Pharmaceuticals (NASDAQ: ANIP) to $73.00 (from $63.00) while maintaining a Strong Buy rating following another strong quarter.
Wilbur said they believe the outperformance in 4Q18 as well as solid initial 2019 guidance... More
